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Abstract: The 2017 consensus report of the Asia Dry Eye Society (ADES)
on the definition and diagnosis of dry eyes described dry eye disease as
“Dry eye is a multifactorial disease characterized by unstable tear film
causing a variety of symptoms and/or visual impairment, potentially accom-
panied by ocular surface damage.” The report emphasized the instability of
tear film and the importance of visual dysfunction in association with dry
eyes, highlighting the importance of the evaluation of tear film stability.
This report also discussed the concept of tear film–oriented therapy, which
stemmed from the definition, and which is centered on provision of
insufficient components in each tear film layer and ocular surface epithe-
lium. The current ADES report proposes a simple classification of dry eyes
based on the concept of tear film–oriented diagnosis and suggests that there
are three types of dry eye: aqueous-deficient, decreased wettability, and
increased evaporation. It is suggested that these three types respectively
coincide with the problems of each layer: aqueous, membrane-associated
mucins, and lipid/secretory mucin. Although each component cannot be
quantitatively evaluated with the current technology, a practical diagnosis
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based on the patterns of fluorescein breakup is recommended. The Asia Dry
Eye Society classification report suggests that for a practical use of the
definition, diagnostic criteria and classification system should be integrated
and be simple to use. The classification system proposed by ADES is
a straightforward tool and simple to use, only through use of fluorescein,
which is available even to non-dry eye specialists, and which is believed to
contribute to an effective diagnosis and treatment of dry eyes.
Key Words: Asia Dry Eye Society—Classification—Dry eye—Tear
film–oriented therapy—Tear film stability.
(Eye & Contact Lens 2020;46: S2–S13)
T he Asia Dry Eye Society (ADES) was founded in 2012 inTokyo by Korean, Chinese, and Japanese dry eye specialists
(http://asia-dry-eye.biz). The aim of the society was to facilitate
collaborative research, encourage mutual communication, and gen-
erate agreements on the essential fields such as the definition of dry
eye, diagnostic criteria, and classification. The first agreement on
the definition was achieved in October 2014 in Tokyo after which
the new definition and diagnostic criteria proposal were published
in the January 2017 issue of The Ocular Surface.1 This consensus
was made through extensive discussion over the years with ADES
member countries. The definition emphasized the importance of an
unstable tear film as the most important mechanism for the devel-
opment of dry eye. Because the normal corneal sensation is asso-
ciated with a stable and healthy tear film, an unstable tear film
induces discomfort and pain via a possible increase of tear osmo-
lality. An unstable tear film is also known to affect vision, because
an irregular tear film over the visual axis has been reported in
studies using the tear film stability assessment system, ocular aberr-
ometers, and functional visual acuity systems.2–4
With the emergence of new aqueous tears and/or mucin secreta-
gogue eye drops containing diquafosol sodium (Diquas) or rebamipide
(Mucosta) and based on the accumulating evidence in relation to their
favorable effects on the tear film and ocular surface epithelium,5–31 we
took further steps to emphasize the importance of a stable tear film of
dry eye patients in Asia. These two eye drops work to increase tear
breakup time by increasing aqueous and or mucin components to the
ocular surface.5,32 Many earlier reports have pointed out the impor-
tance of a stable tear film in ocular surface health.33–35
In this consensus paper, we would like to introduce our new
classification system for dry eye based on the ADES definition.1
For the daily practice of dry eyes, a simple and practical definition
and evidence-based diagnostic criteria are mandatory. Because
there are two types of dry eye that includes aqueous deficient
and evaporative dry eye, the latter for which meibomian gland
dysfunction (MGD) is responsible as the major cause, the clinicians
need a straightforward classification, which may be useful for
determining the most useful treatment. Thus, discussion on classi-
fication was initiated in ADES to fulfill this need.
Along with the definition consensus meetings, the classification
discussion also began concurrently with preliminary discussion in
November 2014. After completion of the definition consensus, we
continued the discussion of classification. However, because TFOS
DEWS II started in April 2015, we decided to postpone the
classification discussion until TFOS DEWS II was published to
avoid the possible conflict of interest. The final meeting was held in
Osaka on October 20, 2017.
BACKGROUND OF ASIAN COUNTRIES FOR A
REGIONAL CONSENSUS
First, in Asia, optometrists are not involved in clinics of dry eye
disease, but only ophthalmologists. The base membership of
ADES believed that there was a need for simple and effective
examination methods that could appeal to ophthalmologists and be
used as a guide in Asian countries. Second, in Asian countries, in
contrast to North America and continental Europe, it has become
possible to prescribe secretagogue eye drops that can treat dry eye
disease. Another important point is that Japan and most Asian
countries have access to diagnostic tools and imaging technology
that help to view and assess the lipid and the aqueous layers. These
led to the evolution of the concept of tear film–oriented therapy
(TFOT), that is, evaluation and treatment tailored to the problems
in each layer. Third, epidemiological studies have shown that dry
eye prevalence in Asia is higher than in Europe and the United
States. Moreover, their epidemiological studies showed that short
BUT type of dry eyes are prevalent in Japan and in other Asian
countries, compared with other types of dry eye disease.36,37 With
such a background, ADES was launched in 2014, and Asian dry
eye clinicians met together, and the current definition of dry eye
and diagnostic criteria were reported.1 After that, discussions
continued further in ADES, leading to the present classification.
HISTORY OF THE CLASSIFICATION OF DRY EYE
The first comprehensive classification of dry eye was published
in 1995 on the basis of consensus from the NEI/Industry working
group on Clinical Trials in Dry Eye.38 In the 1995 report, dry eye
was divided into 2 primary categories; tear-deficient and evapora-
tive. These two subgroups were further subclassified according to
a range of intrinsic and extrinsic etiological factors. It is of note that
in this report, dry eye was defined as “a disorder of the tear film due
to tear deficiency or excessive tear evaporation” suggesting that dry
eye caused either by tear deficiency or excessive evaporation were
exclusively considered to be the main categories of dry eye. Since
then, this classification scheme has had a great impact on dry eye
research and clinical practice. The scheme was basically retained in
the DEWS report published in 2007 (Fig. 1).39 Aqueous deficient
dry eye (coined as “tear-deficient” in the NEI report) was further
classified into Sjogren and non-Sjogren categories. Evaporative dry
eye was sub classified into intrinsic and extrinsic categories, and
they were further classified according to etiological factors.
The classification system also took its place in the recent TFOS
DEWS II report with some modification.40 The newly proposed
classification scheme considers the cases where patients exhibit dry
eye symptoms without evidence of obvious signs, or present with
marked signs, but lack of dry eye symptoms. The former includes
cases with neuropathic pain where the somatosensory system is
affected, and the latter is related to the reduced corneal sensitivity
(neurotrophic condition) (Fig. 2). Eyes with both signs and symp-
toms were classified into either aqueous deficient or evaporative
dry eyes. Although this part of classification is basically the same
as the previous classifications, there is a slight modification to
clarify that there are a significant number of eyes that have both
aqueous deficient and evaporative components, and that these two
subcategories were not exclusive.
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There are other groups which have proposed various classifica-
tion systems. In Asia, Chinese scholars proposed their dry eye
classification in 2004.41 It proposed a method based on the struc-
ture of tear film and tear dynamics. Dry eye was divided into five
types, including lipid deficient dry eye (evaporative dry eye), aque-
ous deficient dry eye, mucin deficient dry eye, abnormal tear
FIG. 1. Major etiological cause of dry eye in TFOS
DEWS report in 2007. Reprinted from the ocular
surface, Vol 5(2), the definition and classification of
dry eye disease: Report of the definition and classifi-
cation subcommittee of the International Dry Eye
Workshop (2007), pages No. 75–92, copyright
2007, with permission from Elsevier.
FIG. 2. Classification of dry eye disease in TFOS DEWS II. Reprinted from the ocular surface, Vol 15(3),
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report, pages 276–283,
copyright 2017, with permission from Elsevier.
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dynamics dry eye, and mixed dry eye. The Chinese dry eye con-
sensus subsequently adopted this classification.42 The classification
based on the structure and tear film dynamics is very helpful for the
treatment of different types of dry eye. In 2005, Murube et al.43
published an article entitled “The triple classification of dry eye for
practical use”. His classification consisted of the three following
aspects: etiopathogenesis, affected glands/tissues, and grade of
severity. In relation to etiopathogenesis, dry eye was classified into
the following 10 subcategories; age-related, hormonal, pharmaco-
logic, immunopathic, hyponutritional, dysgenetic, adenitic, trau-
matic, neurologic, and tantalic. In a classification according to
the affected glands/tissues, there were the following five subcate-
gories; aqueous deficient, lipid deficient, mucin-deficient, epithe-
liopathic, and nonocular exocrine-deficient. Murube’s classification
systems emphasized more of the physiological or pathological
abnormalities in dry eye compared with those proposed by those
in NEI/DEWS/TFOS DEWS II.
There is also a classification system, the Delphi approach,
proposed by dry eye specialists in the United States and Europe.44
In their report, dry eye is viewed in relation to the presence or
absence of lid margin disease, and tear distribution abnormalities
(Fig. 3). The Delphi classification was based on the treatment
algorithm for dry eye patients, and different treatment methods
were described in each subcategory.
NEW DRY EYE CLASSIFICATION BASED ON
THE TEAR FILM–ORIENTED
DIAGNOSIS CONCEPT
Dry eye was reported as Sjogren syndrome related dry eye in
1933. This is a typical form of decreased aqueous secretion and
was considered the classic type of dry eye. However, according
to the recent epidemiological study targeting office workers,
most dry eye showed tear film instability and ocular surface
abnormalities without reduction in tear secretion, and this short
BUT type is now more dominant than the so-called classic
type.45
An unstable tear film can be caused by several mechanisms. Any
ocular surface components comprising those of tear film and surface
epithelium can affect the tear film stability, including lipids, aqueous/
secretory mucins, and membrane-associated mucins. An abnormality
in the lipid components is thought to accelerate tear evaporation,
resulting in an unstable tear film, despite big discussions as to the
suppression of the tear film lipid layer on the evaporation of aqueous
tears from aqueous layer.46–52 Aqueous tear deficiency is the classical
type of dry eye, including Sjogren syndrome, which of course is
associated with an unstable tear film due to aqueous tear deficiency.
Decrease of secretory mucins may be involved in the unstable tear
film.53–56 Deficiency of membrane-associated mucin decreases the
wettability of the cornea and conjunctiva, and may contribute to the
stability of tear film and their deficiency may shorten the tear film
breakup time. Asia Dry Eye Society discussions led to a dry eye
classification based on the components of two-layered tear film and
of the surface epithelium (Fig. 4). However, a mixed type of dry eye
may exist. It should be noted that TFOS DEWS II classification has
shown that it is difficult to strictly distinguish between the aqueous
deficient type dry eye and the increased evaporative type, and a hybrid
form has been proposed. Asia Dry Eye Society classification scheme
is valuable for the concept of TFOT (Fig. 5). Because this classifica-
tion is principally based on the abnormalities of the components of
each tear film layer and the ocular surface epithelium, the diagnosis
itself automatically leads us to TFOT. When the lipid layer is abnor-
mal, such as due to MGD, then treatment for MGD becomes the
obvious approach for dry eye. When the aqueous tear secretion is
deficient such as in Sjogren or non-Sjogren aqueous tear-deficient type
of dry eyes, aqueous components should be provided by artificial
tears, hyaluronic acid, or tear secretagogues such as diquafosol
sodium, or using punctal plugs in combination with eye drops. When
the secretory mucin and membrane-associated mucin is abnormal, the
mucin components should be provided to the ocular surface such as by
mucin secretagogues such as diquafosol sodium or rebamipide. Our
classification scheme automatically finds the way to an appropriate
treatment modality (Fig. 6). Although we categorized dry eye disease
into three types according to the tear film abnormality or epithelial
FIG. 3. Dry eye disease classification in
Delphi approach (2006). Reprinted from
cornea, Vol 25, Behrens A, Doyle JJ,
Stern L, et al. Dysfunctional tear syn-
drome: A Delphi approach to treatment
recommendations, pages 900–7, copy-
right 2006, with permission from Wol-
ters Kluwer.
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surface abnormality, not all patients are diagnosed with only one of
these categories and a mixed type diagnosis can exist. In the TFOS
DEWS II report, patients may have aqueous tear deficiency and MGD
together, or they may have MGD and a decrease of membrane-type
mucin abnormalities together. Therefore, it may be necessary to go
through several steps in treatment as well.
Tear film–oriented diagnosis (TFOD) concept is important not
only from the aspect of discomfort, but also from the impairment of
vision which is related to dry eye, because tear film instability
disturbs the light entering the eyes, by increasing the scattering and
optical aberrations. It is well known that dry eye decreases the
quality of vision in daily life from driving to reading. An unstable
tear film can explain such deterioration in visual experiences. Many
studies on functional visual acuity in dry eye conditions and
increased aberrations as assessed by aberrometers support this
hypothesis.57–61
FIG. 4. New dry eye disease classifica-
tion by the Asia Dry Eye Society.
FIG. 5. The concept of tear film-ori-
ented therapy. *Diquafosol sodium may
increase the function of the tear film
lipid layer by promoting spreading of
the lipid layer through lipid and tear
fluid secretion. **Rebamipide may sup-
press the inflammation of the ocular
surface in dry eye by its anti-inflamma-
tory action. Figure provided by Dry Eye
Society Japan.
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Asia Dry Eye Society also discussed the dynamic aspects of dry
eye disease in relation to the etiology or classification. A decreased
blink rate in visual display terminal (VDT) workers may increase
tear evaporation,1,62,63 thus this type can be categorized as evapo-
rative dry eye. Lagophthalmos is a condition in which the eye
remains open all the time, thus too much evaporation occurs and
consequently damages the ocular surface epithelium and thus it can
be categorized as evaporative dry eye. So, whatever the reason for
the particular classification, we can still classify dry eye based on
the abnormalities in two-layer components of tear film and in
ocular surface epithelium. A more detailed discussion is provided
in each section of the three classifications (Fig. 4).
Subjective symptoms and objective findings-oriented severity scales
have been considered in the diagnosis and treatment of dry eyes. In the
2007 DEWS report, there is a table showing the severity of objective
findings and severity of subjective symptoms.39 In the TFOS DEWS
II report, the severity matrix table was eliminated. Because the signs
and symptoms do not always match in dry eye disease,64–66 this table
was not regarded as practical by ADES, although there are definitely
mild, moderate, and severe dry eyes based on the symptoms. Accord-
ing to the ADES agreement in the previous consensus paper, the dry
eye disease severity was not thought to be related to the ocular surface
condition. As we will cover in the final section of this paper, the
severity is more related to the neuropathic pain components. Thus,
it was decided not to include severity as a classification component.
The subjective severity is rather the “target” for the treatment whether
the selected treatment is effective or not.
In ADES classification, dry eye is classified into three subtypes:
aqueous deficient type, decreased wettability type, and increased
evaporation type. It should be noted that TFOS DEWS II
classification has shown that it is difficult to strictly distinguish
between the aqueous deficient type and the increased evaporative
type, and a hybrid form has been proposed.
TEAR FILM BREAKUP PATTERNS AND THE
CLASSIFICATION OF DRY EYE
A major breakthrough reported by Yokoi et al.67 for the classi-
fication of dry eye was based on the fluorescein breakup patterns.
Tear film breakup occurs because of various reasons including
increased evaporation, decreased aqueous tear volume, and
decreased wettability of corneal surface, which resulted in different
patterns of fluorescein breakup (Fig. 7). The detailed pattern of
each classification is described later, but the fundamental point is
very simple. If dry eye occurs because of aqueous deficiency, line
or area breakup patterns are dominant. When the dry eye occurs
because of a lipid deficiency, the breakup pattern is the random
type. Decreased wettability type results in showing spot or dimple
breakup patterns as representative breakup patterns.
To obtain a reproducible breakup pattern, it is necessary to put
a small amount of fluorescein into the eye. Specifically, after
wetting the fluorescein test paper, it is shaken to remove excess
dye, and the test paper is placed on the edge of the lower eyelid.
Also, by having the patient open their eyes quickly, it is possible to
detect any hidden abnormality in the tear film.
The dry eye diagnosis in ADES concept is also tear film-
oriented, because diagnosis of aqueous deficiency, decreased
corneal wettability, or increased evaporation is done from the
breakup pattern of the tear film. The TFOS DEWS II report
suggests that the Schirmer test is an invasive test. In contrast, the
current consensus acknowledges that aqueous deficiency can be
detected by Schirmer test without anesthesia, meniscometry, and
strip meniscometry. In dry eye clinical routine, Schirmer test
without anesthesia should be done at least once to evaluate the
possibility of aqueous deficiency. Moreover, for the diagnosis of
lipid deficiency, lipid layer interferometry is to be used to evaluate
decreased lipid thickness in patients with dry eye, but it is not
widely used. In a practical way, presence of MGD and poor
Meibomian gland expressibility determined by manual pressure to
the eyelid can be used to diagnose lipid deficiency. The current
challenge for the TFOD is the decreased wettability dry eye,
namely the deficiency of membrane-associated mucin.
Although several studies have provided evidence that the short
BUT type of dry eye, which includes evaporative and decreased
wettability dry eye is related to decreased mucin components in the
tear film layer and the surface epithelium,45,68,69 there is no easy
method to evaluate the mucin layer. This area should be investigated
further in the near future, but for the time being, tear film breakup
patterns can provide a clue not only to the diagnosis of evaporative
and decreased wettability dry eye (Fig. 7). Moreover, repeatability of
tear film breakup pattern should be studied in future studies.
Aqueous Deficient Dry Eye
This classic type of dry eye was first described in association
with Sjogren syndrome in 1933 and later with non-Sjogren
aqueous deficiency type. Because aqueous components decrease,
the tear film layer becomes incompletely established with very
unstable tear film. When tears are almost nonexistent as in Sjogren
syndrome, the tear film layer is not established after a blink. In this
situation, “area break” can be observed (Figs. 4 and 7). The aque-
ous deficient dry eye with limited or no reflex tear secretion is also
associated with severe dry eyes such as seen in patients with
chronic graft-versus-host disease (cGVHD), ocular cicatricial pem-
phigoid, or Stevens-Johnson syndrome. According to the compen-
sation theory of the tear film, this type of dry eye may have a very
thick lipid layer compensating for the aqueous tear components,
occasionally accompanied by increased mucin production resulting
in the too much discharge.70 Aqueous tear deficiency is known to
FIG. 6. Tear film-oriented therapy based on dry eye disease classi-
fication by ADES. ADES, Asia Dry Eye Society.
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be associated with thicker lipid layer and accumulated mucus. This
accompaniment is supported by the compensation theory,70 where
decreased production of aqueous is compensated by the increased
production of lipids from meibomian glands and increased mucins
from goblet cells. However, this may be explained by the delayed
aqueous tear clearance.71,72
Typical aqueous tear-deficient dry eye shows a “line break” as
the breakup patterns (Fig. 7). The “line break” can be observed
during the upward movement of fluorescein-stained aqueous tear
after the eye is opened at the inferior part of the cornea. Aqueous
tear-deficient dry eye is often accompanied by the superficial punc-
tate keratopathy and this should be the result of the repeated
breakup. The aqueous deficient dry eye is diagnosed by Schirmer
test without anesthesia. According to the ADES consensus,
Schirmer test without anesthesia of less than or equal to 5 mm in
5 min is considered to be aqueous tear-deficient. When it is more
than 5 mm, but less than or equal to 10 mm, it is considered to be
moderate aqueous tear deficiency, because a normal value is more
than 10 mm. Video interferometry is also a useful methodology in
this diagnosis. Video interferometer mainly observes the lipid
layer, but it can predict the aqueous condition because the lipid
layer spreads by each blink when the proper aqueous components
exist. If the aqueous components are absent, we can see that the
upwardly spreading lipid layer is undetectable by interferometry.73
Tear meniscus observation also provides a clue for tear
deficiency via meniscometry (or strip meniscometry).73–75 When
the strip meniscometry is less than 4 mm in 5 sec, a diagnosis of
aqueous tear deficiency can be made.76
The tear-deficient type of dry eye includes Sjogren syndrome,
ocular cicatricial pemphigoid, Stevens-Johnson syndrome,
cGVHD, and non-Sjogren type dry eye, such as seen in long-
term VDT users.77–89 The mechanism of non-Sjogren type aqueous
deficiency is unknown, but there is a hypothesis that long-term use
of VDT induces a lacrimal gland hypo-function resulting in accu-
mulation of excess secretary vesicles in the acinar cells which
cannot be secreted with normal stimulation (Fig. 8).77,79
In treatment, aqueous deficiency type of dry eye requires
replacement of necessary aqueous components. Eye drops such
as the artificial tear substitutes also supply the lacking components
of the tear film. Hyaluronic acid and carboxymethylcellulose are
eye drops that supplement the aqueous layer, and these negatively-
charged and high molecular weight polymers can retain water in
the aqueous layer. Artificial tears or hyaluronic acid eye drops are
usually preferred as the initial line of therapy, but their residence
time for the ocular surface are temporary, say 3 or 5 min.73 Tear
secretagogues such as diquafosol sodium are currently the first
choice of treatment (Fig. 6). Studies have shown that the staining
score decreased compared with baseline from 2 weeks of diquafo-
sol treatment,90,91 and efficacy increased with longer use of diqua-
fosol sodium.91 When a quicker therapeutic efficacy is necessary,
punctal plug becomes the choice of treatment. There are proven
evidences which showed the efficacy of punctal plug treatment for
aqueous deficient type dry eye disease.73,92,93 Punctal occlusion
improves not only the aqueous components, but the lipid and
mucin components as well, because it sustains all the three tear
film layer components because of the delayed aqueous tear clear-
ance as stated above. A combination of punctal plug with diqua-
fosol sodium may provide immediate and long-term relief, and is
also a viable treatment approach.
Anti-inflammatory treatment is also important, and it is believed
that instability of the tear film increases the friction between the
eyelids and the eye, which will result in ocular inflammation due to
epithelial damage. T cells play an important role in dry eye onset.
Cyclosporin A reduces T-cell activation via IL-2. Several studies
have reported improvement in symptoms, improvement in tear
stability, and improvement in tear secretion. Also, recently, 5%
lifitegrast has been FDA approved. This drug mimics the ICAM-1
cell adhesion molecule and blocks the interaction between ICAM-1
and lymphocyte function-related antigen (LFA-1), which influen-
ces T-cell migration and activation. Phase 3 clinical trials reported
improvement in dry eye symptoms and vital staining scores.94
FIG. 7. Classification of fluorescein
breakup patterns.
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Patients with Sjogren syndrome, cGVHD, ocular cicatricial
pemphigoid, or Stevens-Johnson syndrome may require special
attention because of the severity and immune-orientated disease.
For those patients, control of autoimmune reaction by steroids or
immunosuppressants such as cyclosporine may become neces-
sary.88,95–99 For the severe aqueous tear-deficient dry eye, autolo-
gous serum eye drops are sometimes necessary to provide the
essential tear components to the ocular surface epithelium.96,100,101
In addition, consultation with an internal medicine specialist for the
systemic evaluation is recommendable.
Increased Evaporation Dry Eye
This type of dry eye may be caused by the lack of lipid or
abnormal quality of lipid resulting in an unstable tear film. The
most frequent representative condition is thought to be
MGD.102–105 This type provides the “random break” as a breakup
pattern (Figs. 4 and 7), because pure lipid deficiency type has
normal aqueous and mucins. According to the compensation
hypothesis, pure MGD patients have an increased aqueous tear
volume to compensate the lipid layer deficiency to try to stabilize
the tear film.70 In addition to the pattern of “random break,” lipid
layer interferometry is the supplementary equipment to observe the
lipid deficiency type of dry eye. The lipid layer is measured as
more than 40 mm in this system, but it is less than 40 mm when
lipid deficiency occurs. Video interferometer is also a useful tool
for the observation of lipid deficiency in addition to the “random
break” pattern observed during BUT testing.
For the treatment, the primary target is thought to be the
meibomian gland, although meibomian lipids may have limited
action to suppress aqueous evaporation from the tear film.46 Lid
hygiene is the first choice of treatment using lid scrubs or eye
shampoo.106–112 Small amounts of lipid or lipid-containing eye
drops are reported to be effective.108 Recently, washing with an
ointment is reported to be effective in keeping the meibomian
orifices open.113
Warming of the lids by heated towels is also a simple and long-
standing treatment. Eye warming devices such as infrared LED
devices or disposable eye warming masks are gaining in popularity
in Asia.114–116 Since the problem of the lipid deficiency resulting in
excessive evaporation, suppression of evaporation by increased
ambient humidity is another strategy. Not only increasing the room
humidity, but the local environment around the eye is an important
target. Goggles, moisture glasses and moisture devices are the
choices of treatment for lipid deficiency type of dry eye.
Decreased Wettability Dry Eye
This type of dry eye may be increasing with the increase in VDT
users.45 The characteristic phenotype is the so-called short BUT
type dry eye in which BUT is short but the tear production is
normal and staining is none or slight. Toda et al.33 originally
reported short BUT dry eye in 1995 which mainly included this
type of dry eye and increased evaporation dry eye.
Because the membrane-associated mucin is deficient or abnor-
mal, the wettability of the surface of the cornea becomes impaired.
According to the DEWS or TFOS DEWS II consensus reports of
dry eye, this type is categorized as “evaporative” with lipid defi-
ciency type, but the fundamental mechanism of the disease is com-
pletely different. The representative patterns of tear breakup in this
category are “spot break” or “dimple break.” These types of
breakup pattern appear respectively during the phase of deposition
of aqueous tears on the cornea immediately after eye opening or
during the phase of upward movement of aqueous tears before the
establishment of precorneal tear film. Especially for the “spot
break” (Fig. 7), BUT is very short corresponding to 0 sec. In this
breakup pattern, breakup occurs during eye opening, which means
breakup already exists when eye opening was completed. In the
recent reports, rapid expansion of the breakup is proposed as a mod-
ification of some breakup patterns that are possibly associated with
a decreased corneal wettability mechanism and are often seen in
the short BUT type dry eye.117,118 The patient’s complaint of
decreased wettability dry eye is relatively obvious and was usu-
ally difficult to treat except by punctal plug. Recently, it has been
reported that the amount of ocular surface glycocalyx signifi-
cantly correlated with tear film breakup time (Fig. 9).119 From
this result, eyes with “spot break” as the breakup patterns should
have a localized membrane-type mucin deficiency at the cornea.
After the introduction of rebamipide and diquafosol sodium, the
mucin layer deficiency can now be treated adequately120 and thus
the unstable tear film due to the mucin deficiency has now
become treatable.
Tear Dynamics and Dry Eye Development
In addition to the three-layer classification that includes the two-
layered tear film and the surface epithelial layer, the ADES report
emphasized the role of tear dynamics such as decreased blink, lid
deformity, low environmental humidity, lagophthalmos, conjunctivo-
chalasis, and the other ocular surface diseases with decreased tear
clearance. Those factors may affect the tear film stability and thus can
constitute to an independent classification. However, the treatment for
decreased blinking or excessive evaporation eventually falls into one
FIG. 8. Lacrimal gland hypofunction in visual display terminal
(VDT) users and animal model. Upper Figures: Rat VDT user model
causes alterations in lacrimal gland morphology. Electron micro-
scopic analysis of acinar cells of normal and VDT rat model. Images
showing expanded acinar cells accompanied by accumulated
enlarged secretory vesicle in the cytoplasm, decreased endoplasmic
reticulum. Scale bar ¼ 10 micrometers. Lower Figures: Electron
microscopic findings of the lacrimal gland acinus in human normal
and VDT user. Homogeneous secretory vesicles in normal controls.
Scale bar ¼ 5 micrometers. High magnification view of secretory
vesicles in the VDT user. Red arrows, arrowheads and asterisk show
nuclei, secretory vesicles and ductal lumen, respectively. Figures
from77,79 Nakamura et al. and Kamoi et al., respectively. These are
open access articles distributed under the terms of the Creative
Commons Attribution License.
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or two layers of tear film including lipid layer and aqueous layer. If
excessive tear evaporation occurs because of less blink or lagoph-
thalmos, the basic treatment is the same, in addition to targeting each
specific treatment such as lid closure or ointment application during
sleep for lagophthalmos. Visual display terminal users with decreased
blink may need education on the importance of blinks.
Special Subtypes of Dry Eye
As we have described earlier, special subtypes of dry eye exist
such as Sjogren syndrome, GVHD, ocular cicatricial pemphigoid,
and Stevens-Johnson syndrome for which special attention should
be paid. In addition, there are certain types of conditions that affect
the stability of the tear film. These are conjunctivochalasis, contact
lens wear, superior limbic keratoconjunctivitis, and nocturnal
lagophthalmos.
NEUROPATHIC PAIN COMPONENT AND
SUBJECTIVE SEVERITY
The Asia Dry Eye Society discussed about a possible
classification for the severity of the dry eye disease with
subcategories such as mild, moderate, and severe dry eyes.
For therapeutic purposes, the severity does not give us enough
information, because the symptoms do not directly correlate
with the severity of the sign(s). An original report of the short-
BUT-type of dry eye in 1995 clearly showed that the symptoms
of a patient can be almost as severe as that in a patient with
Sjogren syndrome, except that there was no observable ocular
surface damage.33 Now it is speculated that neuropathic com-
ponents exist even in the ordinary type of dry eye, where the
neuropathic components determine the severity of symptoms.
Thus, we concluded that subjective severity could be used as
a marker for the therapeutic efficacy, but not for the purpose of
classification. In other words, we classified dry eyes according
to the two tear film layers and the surface epithelium, increased
evaporation, aqueous-deficient and decreased wettability types
for various treatment options, but the therapeutic efficacy
should be evaluated by the symptoms such as dry eye–related
pain, discomfort, or visual disturbances.
CONCLUSION
The ADES proposes a simple classification of dry eyes
based on the concept of TFOD according to the definition
report proposed previously.1 There are basically three types of
dry eye: increased evaporation, aqueous-deficient, and
decreased wettability. These three types coincide with the
problems of each layer: lipid, aqueous/secretory mucin, and
membrane-associated mucin. Although each component can-
not be quantitatively evaluated with exact precision with the
current technology, we can make a practical diagnosis using
the patterns of tear film breakup simply using fluorescein. The
“random break” corresponds to the increased evaporation dry
eye (evaporative dry eye), and “line break” and “area break”
correspond to the aqueous deficient dry eye respectively of
mild-to-moderate and severe in their severity. Decreased wet-
tability dry eye is related to “spot break” and “dimple break”
as representative patterns. These three simple classifications
lead us to select the choices of treatment to target the impor-
tant layer of tear film and the surface epithelium, each of which
maintains tear film stability.
For a practical use of the diagnostic criteria system, definition,
diagnostic criteria, and classification should be integrated and be
simple to use. The classification system proposed by ADES is
a straightforward tool and practical, because it only uses fluores-
cein, even for non-dry eye specialists, which can contribute to an
effective diagnosis and treatment of dry eyes.
Because the fluorescein breakup pattern is one of the tear film-
oriented diagnostic methods derived from physical theory and
clinical findings, the relationship with the ocular surface mucins
and the tear film lipid layer needs be clarified in future studies. We
are convinced that the suggestions of this paper may be used as
a guide, and serve as a basis for further discussions for the future
dry eye workshop meetings.
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